ZILRETTA decreased peak systemic exposure

18x lower peak plasma concentration with ZILRETTA

Reduced peak systemic exposure to triamcinolone acetonide (TA) (1144 pg/mL) compared to TAcs (21,062 pg/mL)*

Joint residence time chart
  • Results based on a study evaluating concentration of TA in plasma following a single intra-articular injection of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) (n=60) or TAcs (n=18)2
    • ZILRETTA: Blood samples were collected periodically over 24 hours and at Weeks 1, 6, 12, 16, and 20
    • TAcs: Samples were collected periodically over 24 hours and at Week 6
*

Based on Cmax levels following a single intra-articular injection of ZILRETTA and TAcs.

TAcs=triamcinolone acetonide crystalline suspension.

Minimal increase in blood glucose levels vs TAcs in patients with controlled type 2 diabetes

  • Results based on a pharmacodynamic study evaluating a single injection of ZILRETTA or TAcs in patients with orally controlled Type 2 diabetes; primary endpoint was the change in average blood glucose 72 hours pre-injection compared with 72 hours post-injection1
  • ZILRETTA demonstrated a statistically significantly smaller LS mean change (14.7 mg/dL vs 33.9 mg/dL; P=0.0452)1
    • ZILRETTA: Average glucose values were 155.2 mg/dL pre-injection and 163.4 mg/dL (range: 89.8 mg/dL to 298.8 mg/dL) post-injection1,3
    • TAcs: Average glucose values were 161.7 mg/dL pre-injection and 198.8 mg/dL (range: 135.1 mg/dL to 315.8 mg/dL) post-injection1,3
  • Corticosteroids may increase blood glucose concentrations; effects on blood glucose can vary widely from patient to patient and may differ from the results seen in this study

The clinical relevance of this plasma exposure and blood glucose information is unknown

Control was defined as HbA1c ≥6.5% and <9.0% at screening.
LS=least squares.